Colorectal cancer patients with tumors harboring KRAS mutation are excluded from receiving the otherwise beneficial therapy of anti-EGFR monoclonal antibodies, and currently have no alternate FDA-approved treatment options available. Here, EGFR is linked to colorectal cancer.